Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339621 | 0.74 | TP53 (0.41) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL7017923 | 0.74 | TP53 (0.44) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL18726784 | 0.74 | TP53 (0.41) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL5317523 | 0.74 | TP53 (0.41) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL8830969 | 0.74 | TP53 (0.41) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL25468618 | 0.74 | TP53 (0.41) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL23228232 | 0.74 | TP53 (0.38) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL1106478 | 0.74 | PDE4A (0.43) | DYRK1AMEN1TP53PABPC1KMT2A | |
| SCHEMBL24198356 | 0.74 | TP53 (0.38) | MEN1TP53PABPC1KMT2AALDH1A1 | |
| SCHEMBL8970101 | 0.74 | MEN1 (0.51) | DYRK1AMEN1TP53PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5084453-A | Antibiotics, bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-28 | — | — | US | claimed |
| JP-9202774-A | — | — | None | — | — | JP | disclosed |
| CN-122011353-A | Imidazopyridine catalyst for liquid crystal polyarylester synthesis and application thereof | 浙江海利得科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| WO-2023212549-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-6096758-A | 3-METHYLIMIDAZOPYRIDINES USED FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-08-01 | — | — | US | disclosed |
| US-6096758-A | 3-METHYLIMIDAZOPYRIDINES USED FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-08-01 | — | — | US | disclosed |
| EP-0882048-A1 | 3-METHYLIMIDAZOPYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-12-09 | — | — | EP | disclosed |
| US-5723468-A | COGNITION ACTIVATORS FOR MEMOY LOSS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
| JP-H09202774-A | 2-ARYLQUINOLINE AND ITS PRODUCTION | GREEN CROSS CORP:THE | 1997-08-05 | — | — | JP | disclosed |
| WO-1997027192-A1 | 3-METHYLIMIDAZOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-07-31 | — | — | WO | disclosed |
| EP-0786460-A2 | 2-Arylquinolines and process for producing the same | ASAHI GLASS COMPANY LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-5571819-A | Imidazopyridines as muscarinic agents | WYETH | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | GRM5 1246/4885DYRK1A 3696/4885ACVR1 2616/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | GRM5 130/4885DYRK1A 3616/4885ACVR1 4669/4885 |
| US-20230312605-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | GRM5 1655/4885DYRK1A 1/4885ACVR1 1564/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GRM5 130/4885DYRK1A 3616/4885ACVR1 4669/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRM5 21/4885DYRK1A 1746/4885ACVR1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.